scholarly journals Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine

2020 ◽  
Vol 11 (11) ◽  
pp. 3327-3333
Author(s):  
Fang L.I. Ang ◽  
Andrew Rowland ◽  
Natansh D. Modi ◽  
Ross A. McKinnon ◽  
Michael J. Sorich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Survival Outcomes ◽  
Breast Cancer Patients ◽  
Her2 Positive

Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast cancer patients.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 639-639
Author(s):  
Renata Duchnowska ◽  
Piotr Jan Wysocki ◽  
Konstanty Korski ◽  
Bogumila Czartoryska-Arlukowicz ◽  
Anna Niwinska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive

Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12019-e12019 ◽  
Author(s):  
Alessandra Fabi ◽  
Katia Cannita ◽  
Gianluigi Ferretti ◽  
Mariangela Ciccarese ◽  
Grazia Arpino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Life Effectiveness ◽  
Heavily Pretreated

The rational use of detection of CTC and serum HER2 ECD for HER2-positive advanced breast cancer patients.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12084-e12084
Author(s):  
Jinmei Zhou ◽  
Tao Wang ◽  
Yi Liu ◽  
Huiqiang Zhang ◽  
Shaohua Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Rational Use

Efficacy and safety of neoadjuvant chemotherapy of sequential doublets and dose dense plus trastuzumab in HER2-positive locally advanced breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11089-11089
Author(s):  
E. Grande ◽  
A. Sanchez-Muñoz ◽  
A. García-Tapiador ◽  
A. Ortega-Granados ◽  
A. Jaén-Morago ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Chemotherapeutic Agents ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Number Of Patients

11089 Background: Neoadjuvant therapy for breast cancer constitutes an excellent test to evaluate the sensitivity to chemotherapeutic agents and/or new biological agents against specific targets as trastuzumab and Her2. Furthermore, pathologic complete response (pCR) is a surrogate marker for disease-free and overall survival. Methods: The objective was to determine the efficacy in terms of pCR rates and the safety profile of the doublets plus trastuzumab schedule administered for the neoadjuvant setting of locally advanced breast cancer patients. A total of 20 patients with histologically confirmed locally invasive Her2-positive breast carcinoma were included. The median age was 43. Mean tumour size was 5.1 cm. Treatment consisted of a first sequence with epirubicin 90 mg/m2 and cyclophophamide 600 mg/m2 for 3 cycles, and a second sequence with paclitaxel 150 mg/m2 and gemcitabine 2500 mg/m2 for six cycles. All drugs were administered on day 1, every two weeks with prophylactic growth factor supports. Weekly trastuzumab was administered at a dose of 2mg/kg (4 mg/kg loading dose), concomitantly with paclitaxel and gemcitabine. Subsequently, patients underwent surgery and received radiotherapy and/or adjuvant hormonal therapy according to institutional practice Results: Objective clinical response was achieved in all patients. 10 (50%) pCR were obtained. With a median follow up of 18.2 months (3–38), 17 patients (85%) are alive without disease progression, and 3 (15%) showed recurrence and 1 of whom died. Treatment was well tolerated, 1 patient experienced 1 episode of grade 4 neutropenia and 2 patients had grade 3 neutropenia. 1 patient discontinued the treatment due to hypersensitivity reaction to paclitaxel. Asymptomatic decrease in cardiac ejection fraction with subsequent normalization was seen in 1 case. Conclusions: Despite of the small number of patients, results have shown a high pCR rate in this group of breast cancer patients with poor prognostic. The schedule seems to be feasible and tolerable and further studies with the doublet sequences plus trastuzumab are warranted on the neoadjuvant Her2 positive breast cancer patients No significant financial relationships to disclose.

scholarly journals Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Oncotarget ◽  
2017 ◽  
Vol 8 (61) ◽  
pp. 104149-104159 ◽  
Author(s):  
Renata Duchnowska ◽  
Jeff Sperinde ◽  
Bogumiła Czartoryska-Arłukowicz ◽  
Paulina Myśliwiec ◽  
John Winslow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Predictive Value ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive
Sign in / Sign up

Export Citation Format

Share Document